Myeloproliferative Neoplasms

Rusfertide improved responses vs placebo in phlebotomy-dependent polycythemia vera.

The siRNA divesiran was well-tolerated and reduced the number of phlebotomies that were required in patients with polycythemia vera.

Ruxolitinib plus standard GVHD prophylaxis reduced GVHD in patients with myelofibrosis undergoing transplant.

The combination of seclidemstat and azacitidine will resume study in a phase 1/2 trial in patients with MDS and CMML following a partial clinical hold.

AJ1-11095 is being evaluated in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia.

The JAK/ROCK inhibitor rovadicitinib may provide a safe and effective new treatment option for patients with myelofibrosis who progressed on ruxolitinib.

Mikkael A. Sekeres, MD, discusses the association between smoking intensity, genetic mutations, and disease progression in myelodysplastic syndromes.

Fedratinib showed early improvements in platelet count in patients with myelofibrosis.

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the potential for the use of oral HMAs in MDS.

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the implications of the FDA approval of imetelstat for transfusion-dependent anemia in MDS.

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss other potential roles for luspatercept in MDS and beyond.

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss long-term transfusion independence data for luspatercept in MDS.

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on treatment goals for anemia and transfusion independence in MDS.

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on the FDA approval of luspatercept in ESA-naive lower-risk MDS.

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the importance of treating anemia in myelodysplastic syndrome.

Sangeetha Venugopal, MD, MS, discusses other notable myelofibrosis data from the 2024 ASH Annual Meeting.

Sangeetha Venugopal, MD, MS, discusses data from the BOREAS trial for navtemadlin in relapsed/refractory myelofibrosis.

Sangeetha Venugopal, MD, MS, discusses post hoc overall survival data for pacritinib in myelofibrosis.

Sangeetha Venugopal, MD, MS, discusses the relationship between thrombocytopenia and anemia on disease progression in myelofibrosis

Sangeetha Venugopal, MD, MS, discusses challenges with low-dose ruxolitinib in myelofibrosis.

Treosulfan wins FDA approval for allHCT conditioning in AML and MDS, RP1/nivolumab gets priority review in melanoma, and more this week from OncLive.

The FDA approved treosulfan plus fludarabine for alloHSCT conditioning in acute myeloid leukemia or myelodysplastic syndrome.

Anthony M. Hunter, MD, discusses the development of, and future roles for JAK, BET, and BCL2/BCL-XL inhibitors in myelofibrosis.

Naseema Gangat, MBBS, discusses clinical factors that she uses to choose the optimal JAK inhibitors for individual patients with myelofibrosis.

Craig Eckfeldt, MD, PhD, discusses the current treatment paradigm in MDS and the unmet needs in different subsets of patients.